Retinal Neovascularization
Conditions
Keywords
antiVEGF therapy
Brief summary
The study intends to assess the effect of Avastin injections in different proliferative retinopathies due to different causes
Detailed description
Proliferative retinopathies due to different causes represent important causes for the visual acuity loss. Conventional treatments may sometimes improve the visual function, whereas other times, the visual acuity continue to decrease, in spite of all the medical, surgical or laser treatments. Intravitreal injections with anti-VEGF agents (ex. Avastin for our trial) seem to be an important tool for certain difficult situations in which at the ocular fundus, out of different reasons (advanced age, diabetes mellitus, retinal veins occlusions, etc)new pathologic vessels appear, causing devastating changes in the posterior and anterior segment as well.
Interventions
DRUGAvastin
2,5 mg Avastin intravitreal injections every 4 weeks, 6 months consecutively
Sponsors
Ophthalmological Association Edelweiss
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* clinical diagnosis of a proliferative retinopathy (AGE RELATED MACULAR DEGENERATION,DIABETIC PROLIFERATIVE RETINOPATHY, etc) * distance acuity \< 0.5 * age \> 20 years
Exclusion criteria
* noncooperative patients * ocular infections / inflammations
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The following parameters will be assessed in order to evaluate the Avastin effect: visual acuity, lesions's area at the ocular fundus | one year |
Secondary
| Measure | Time frame |
|---|---|
| The intraocular pressure will be measured during the whole study in order to assess the possible side effects of Avastin injections | one year |
Countries
Romania
Outcome results
None listed